PCM
ERNA icon

Perritt Capital Management’s Eterna Therapeutics ERNA Stock Holding History

Perritt Capital Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$164K – 251
2015
Q2 		$164K Hold
1
– – 0.03% 252
2015
Q1 		$395K Hold
1
– – 0.07% 230
2014
Q4 		$418K Hold
1
– – 0.08% 208
2014
Q3 		$313K Hold
1
– – 0.06% 237
2014
Q2 		$584K Buy
+1
New +$440K 0.1% 203

Other funds holding ERNA

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perritt Capital Management's ERNA Position: Q3 2015 in Review

Perritt Capital Management sold out of Eterna Therapeutics (ERNA) in Q3 2015, closing a stake of 1 share — an estimated $164K sold.

Perritt Capital Management first reported a position in ERNA in Q2 2014 and held it in 5 quarters. The position peaked at $584K in Q2 2014. 6 funds tracked by Wall St. Rank hold ERNA as of Q3 2015.

  • Perritt Capital Management reported no remaining Eterna Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Perritt Capital Management sold 1 Eterna Therapeutics share in Q3 2015, an estimated $164K.
  • Perritt Capital Management first reported a position in Eterna Therapeutics in Q2 2014 and held it in 5 quarters.
  • Perritt Capital Management's Eterna Therapeutics position peaked at $584K in Q2 2014.
  • 6 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2015.

Based on Perritt Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.